ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BMRN / options
ELAN (45) RDY (64) SYRE (55) SMMT (40) ⌘ Pro Terminal β†’

BioMarin Pharmaceutical Inc. (BMRN) Options Positioning, Max Pain & Unusual Sweeps

$57.44 -1.83% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $57.39

BioMarin Pharmaceutical Inc. (BMRN) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (77.7% gross margin, 6% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B β€’ BUY Cap $11.33B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BMRN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $57.44 (-1.83% 1D, market cap $11.33B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, BMRN ranks #37 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BMRN compare to ELAN and RDY in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMRN carries a Roarable B (74/100 RQD), trailing P/E of 31.9x, gross margin of 77.7%, and ROIC of 6.0%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BMRN?
β–Ό

Per BMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001048477), BioMarin Pharmaceutical Inc. generated $3.22B in revenue (+12.9% YoY), $348.9M in net income, and $725.0M in free cash flow against $7.59B in total assets and $597.2M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $57.39 (-0.09%)🧬 Cannibal Buyback (-2.08% YoY Shares)βš™οΈ Cash Engine: 14/20 (B-) β€’ 22.5% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY β€’ 69.4% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B
025507510074
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ Β· Rk A-
Cash (14)Whales (11)SEC (18)Macro (16)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
$75 Bull$62 Base$47 Bear
πŸ“¬ FREE BMRN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BMRN)Realized 20D OHLCV Swing Band: Β±5.7%
Deterministic 5-Pillar Attribution (74/100 Composite)
πŸ” WHY BMRN SCORES 74/100 (B) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 5.57 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 8/9

β–² #2 Bullish Driver: Macro Regime Fit+16/20 pts (22% of score)

FRED Regime Γ— Technicals: 38% of 52W Range β€’ RSI-14 at 54.4 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
66
Grade B-$55.14+0.1% Next Q
Q2 (-2Q)
69
Grade B-$55.21+1.4% Next Q
Q3 (-1Q)
71
Grade B$56.00+2.6% Next Q
Current
74
Grade B$57.44+7.3% Hist 90D Ξ±
Trajectory: B- (66) β†’ B (74)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the BMRN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 74/100 (B) score, BMRN faces multiple-compression risk if 31.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) β€” any gross margin slip below 75.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($60.13) or 200D SMA ($58.47) invalidates the momentum regime and cuts Target Base ($61.58) toward Bear Floor ($47.10).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BMRNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBMRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 74%NO 26%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±5.7%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BMRN)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BMRN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating BMRN & AI Leaders Without Chasing Tops

  • βœ“Institutional whale strikes & implied earnings move audit on BMRN
  • βœ“How disciplined traders manage risk using pre-published trigger & invalidation levels
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BMRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.57%πŸ“ HORIZONTAL RANGE
2026-11-03O $57.49H $58.51L $57.44C $57.44VOL 2.27M
RES: $74.58SUP: $51.75SMA50: $60.13SMA200: $58.47
$72.50$66.20$59.90$53.60$47.31RES $74.58SUP $51.75$57.442026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BMRN Butterfly Map β†’ + Track BMRN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
24.6%/yr Implied 5Y Growth

vs. +12.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BMRN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BMRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BMRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMRN)

Health Care Rank #37 of 1015 βš”οΈ ELAN vs BMRN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BMRN vs. ELAN, RDY, SYRE, SMMT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BioMarin Pharmaceutical Inc. (BMRN) ranks #37 by composite RQD confidence (74/100, grade B) and #96 by equity capitalization ($11.33B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and β€” gross margin. BMRN currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BMRN ACTIVE
BioMarin Pharmaceutical Inc.
B 74/100 31.9x 77.7% 6.0% -1.83% $11.33B Benchmark Subject
ELAN
Elanco Animal Health Incorporated
D 45/100 β€” 55.0% -2.5% +4.51% $11.52B /elan-vs-bmrn β†’
RDY
Dr. Reddy's Laboratories Ltd
C 64/100 32.8x β€” 9.9% -0.28% $11.83B /rdy-vs-bmrn β†’
SYRE
Spyre Therapeutics Inc.
D+ 55/100 β€” β€” -20.0% -1.09% $10.08B /syre-vs-bmrn β†’
SMMT
Summit Therapeutics Inc.
D- 40/100 β€” β€” -35.0% -7.67% $12.82B /smmt-vs-bmrn β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001048477 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioMarin Pharmaceutical Inc. (BMRN) reported GAAP revenue of $3.22B (+12.9% vs. FY2024 revenue of $2.85B , and +33.2% cumulative change since FY2023) , GAAP net income of $348.9M, operating cash flow of $828.0M, and free cash flow of $725.0M (+48.7% YoY). On the balance sheet, BMRN closed FY2025 with $7.59B in total assets against $597.2M in total debt (Altman Z-Score: 5.57, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.22B $348.9M $828.0M $725.0M $7.59B $597.2M
FY2024 (FY) 2024-12-31 $2.85B $426.9M $572.8M $487.4M $6.99B $598.9M
FY2023 (FY) 2023-12-31 $2.42B $167.6M $159.3M $50.4M $6.12B $1.43B

3. BMRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $57.44 (-1.83% 1D, market cap $11.33B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, BMRN ranks #37 in composite RQD confidence.

How does BMRN compare to ELAN and RDY in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMRN carries a Roarable B (74/100 RQD), trailing P/E of 31.9x, gross margin of 77.7%, and ROIC of 6.0%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BMRN?

Per BMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001048477), BioMarin Pharmaceutical Inc. generated $3.22B in revenue (+12.9% YoY), $348.9M in net income, and $725.0M in free cash flow against $7.59B in total assets and $597.2M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BMRN trading relative to its 50-day, 200-day, and 52-week technical levels?

BMRN last traded at $57.44 (-1.83% on volume of 3,264,786 shares), positioning the stock -4.47% below its 50-day simple moving average ($60.13) and -1.76% below its 200-day simple moving average ($58.47). Across its 52-week range of $49.26 to $70.98, BMRN sits at the 37.7% percentile with a 14-day RSI of 54.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±5.7% ($54.17 to $60.71).

Direct Sub-Reports: BMRN RQD Cockpit BMRN 12M Forecast BMRN Earnings & Move BMRN Dividends & DRIP BMRN Insiders & 13F BMRN Whale Options BMRN Profit Sankey BMRN News & Why
ROARABLE RATING BRIEF β€’ RQD 74/100 (B) βœ“ SEC XBRL & RQD VERIFIED

BMRN β€” BioMarin Pharmaceutical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BioMarin Pharmaceutical Inc. (BMRN) earns a live Roarable RQD composite score of 74/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $57.44 (-1.83% 1D, market capitalization $11.33B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 6.0%, gross margin of 77.7%, operating margin of 12.7%, and free cash flow yield of 6.51%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (16/20) + Forensic Balance Sheet (18/20): Incorporates a 0.95x equity beta, Altman Z-Score of 5.57, Piotroski F-Score of 8/9, and Debt/Equity of 0.10x.

2. Business Model, Unit Margins & SEC Financial Trajectory

BioMarin Pharmaceutical Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BioMarin Pharmaceutical Inc. (BMRN) reported $3.22B in annual revenue (up from $2.85B in FY2024, +12.9% YoY) and $348.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.42B revenue, $167.6M net income) through FY2025, BMRN scaled operating cash flow to $828.0M and free cash flow to $725.0M, backed by $7.59B in total assets against $597.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (B β€’ RQD 74/100): Company leadership has skin in the game with net positive insider conviction. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $49.26 – $70.98 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 31.9x trailing P/E and 21.0x EV/EBITDA against 12.7% operating margins and a 0.95x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BMRN carries a macro regime beta of 0.95 and gross margin of 77.7%.

  • Key Question #1: Can BMRN sustain or expand its 12.7% operating margin and 6.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.22B and free cash flow of $725.0M, how will capital allocation balance growth reinvestment against $597.2M in total debt?
  • Key Question #3: How sensitive is BMRN's 26.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?

BMRN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioMarin Pharmaceutical Inc. (BMRN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BMRN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BMRN Bull vs. Bear Conversation Board β€” What's Your Call at $57.44?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BMRN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BMRN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $72.55 (+24.0%)
πŸ“Œ Pinned Debate

The balance sheet is strong, with a Z-Score of 5.57, Piotroski F of 8/9, Debt/Equity of 0.1, and FY 2025 cash of $1.31B exceeding deb

Here is why I am bullish on BMRN here at $58.51: The balance sheet is strong, with a Z-Score of 5.57, Piotroski F of 8/9, Debt/Equity of 0.1, and FY 2025 cash of $1.31B exceeding debt of $597.2M.. Compare BMRN's 12.7% operating margin and 6.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $55.58 are getting bought.

ArenaChamp_24 πŸ‚ BULL

@TapeReader_Pro Agree on the RQD 74/100 quality, though with 0.95 beta I'm scaling in with half-size at $58.51 and keeping dry powder in case we test $54.41.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $48.56 (-17.0%)
Spot @ $58.51

Valuation is rich at a P/E (TTM) of 31.9 and EV/EBITDA of 21 while ROIC is only 6% and net income fell from $426.9M to $348.9M.

I respect the product at BioMarin Pharmaceutical Inc., but the stock at $58.51 is a different story. Valuation is rich at a P/E (TTM) of 31.9 and EV/EBITDA of 21 while ROIC is only 6% and net income fell from $426.9M to $348.9M.. FCF yield is 6.51% and RQD sits at 74/100 (B) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%